Saturday, November 21, 2026

Novo Nordisk Exits Cell Therapy, Hands Parkinson's Program to AI Startup as NVIDIA Locks In Global Pharma Deals

Denmark's Novo Nordisk licensed its Parkinson's cell therapy program to AI-native firm Cellular Intelligence and closed its internal cell therapy unit entirely. NVIDIA's BioNeMo platform meanwhile secured partnerships with Thermo Fisher and Eli Lilly, cementing its position as the backbone of global pharmaceutical AI infrastructure. The moves reflect a widening industry pattern: large drugmakers worldwide are outsourcing experimental modalities to AI specialists rather than building capability i

This article was written by AI. Built from the source documents listed below. How we work

Source Trace Score2 source documents2 with a live linkVerifiability: Strong
Novo Nordisk Exits Cell Therapy, Hands Parkinson's Program to AI Startup as NVIDIA Locks In Global Pharma Deals
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Denmark's Novo Nordisk, whose shares climbed 24.9% over 30 days on strong Q1 2026 earnings, has licensed its Parkinson's cell therapy program to Cellular Intelligence, a US-based AI-native biotech, and shuttered its internal cell therapy division entirely.1

The decision is a clear signal from one of Europe's largest pharmaceutical companies: experimental modalities are being handed to AI specialists, not developed internally.

NVIDIA's BioNeMo platform is the infrastructure layer capturing this shift. The US chipmaker has signed partnerships with Thermo Fisher Scientific and Eli Lilly, giving it direct access to proprietary biological datasets from two of the world's largest life sciences companies.1

Independent adoption is building. Terray Therapeutics and Apheris have each released models built on BioNeMo, extending the platform's reach beyond its anchor partners.1

Competition is intensifying globally. Natera, UK-linked Basecamp Research with its EDEN platform, Boltz Lab, Owkin with OwkinZero, and Edison with Kosmos have all launched competing foundation model platforms in recent months.1 The field has shifted from infrastructure scarcity to a race for differentiation through biology, data quality, and clinical results.

For Novo Nordisk, the restructuring lets it concentrate resources on its dominant GLP-1 franchise: the drug class behind blockbuster obesity and diabetes treatments that has reshaped global pharma valuations. Cellular Intelligence inherits a Parkinson's program with commercial upside.

The broader pattern holds across North America, Europe, and Asia: large pharma is repricing AI drug discovery from speculative bet to embedded R&D strategy. The question now is which platforms control the stack when the first AI-native regulatory approvals arrive.

Source documents

Via News is a conduit. We point to the source documents behind this report: we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score2 source documents2 with a live linkVerifiability: Strong
  1. [1]News articleYahoo Finance· May 11, 2026
    Novo Nordisk Refocuses On GLP‑1 As AI Partner Advances Parkinson’s Bet
  2. [2]News articleYahoo Finance· January 12, 2026
    NVIDIA BioNeMo Platform Adopted by Life Sciences Leaders to Accelerate AI-Driven Drug Discovery

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

Spotted an error? Use “Correct this article” (bottom right), or select any sentence, to report it or respond to that point.

  1. Built from 2 source documents, dated 12 Jan 2026 to 11 May 2026
  2. Published 5 Jun 2026
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›

In this story · Knowledge Files

Via News Editorial Team

The Via News Editorial Team writes analysis and news from the Via News source-traceability system, under the editorial responsibility of L. Miguel Salvado, Editor. Each article is built only from source documents we hold and lists them at the end, so every claim can be checked. Articles generated with AI say so under the byline, as the EU AI Act requires.